Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Eliapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms PAGANINI
- Sponsors Bayer
- 01 Jun 2023 Primary endpoint has been met (Change from baseline in 24-hour cough count (measured by cough recording digital wearable monitoring device) after 12 weeks of intervention) , according to Results published in the Lung.
- 01 Jun 2023 Results published in the Lung
- 06 Sep 2021 According to an Evotec SE media release, data were presented during the virtual European Respiratory Society (ERS) International Congress 2021.